EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 11 (Novembre 2004) Med Sci (Paris), 20 11 (2004) 973-978 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 11, Novembre 2004
Page(s) 973 - 978
Section M/S revues
DOI https://doi.org/10.1051/medsci/20042011973
Published online 15 November 2004
  1. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993; 366 : 575–80. [Google Scholar]
  2. De Luca F, Baron J. Molecular biology and clinical importance of the Ca2+-sensing receptor. Curr Opin Pediatr 1998; 10 : 435–40. [Google Scholar]
  3. Pearce S, Steinmann B. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clin Endocrinol 1999; 50 : 691–3. [Google Scholar]
  4. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8 : 2077–87. [Google Scholar]
  5. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95 : 4040–5. [Google Scholar]
  6. Ye C, Kanazirska M, Quinn S, et al. Modulation by polycationic Ca2+-sensing receptor agonists of nonselective cation channels in rat hippocampal neurons. Biochem Biophys Res Commun 1996; 224 : 271–80. [Google Scholar]
  7. Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R-568 : a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290 : 473–9. [Google Scholar]
  8. Heath H, Sanguinetti E, Oglesby S, Marriott T. Inhibition of parathyroid hormone secretion in vivo by NPS 5-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone 1995; 16 : S85. [Google Scholar]
  9. Lalonde RL, Gaudreault J, Karhu DA, Marriott TB. Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther 1999; 65 : 40–9. [Google Scholar]
  10. Igarashi T, Ogata E, Maruyama K, Fukuda T. Effect of calcimimetic agent, KRN568, on gastrin secretion in healthy subjects. Endocrinol J 2000; 47 : 517–23. [Google Scholar]
  11. Silverberg SJ, Bone HG, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337 : 1506–10. [Google Scholar]
  12. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88 : 5644–9. [Google Scholar]
  13. Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83 : 1083–8. [Google Scholar]
  14. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100 : 2977–83. [Google Scholar]
  15. Wada M, Ishii H, Furuya Y, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53 : 448–53. [Google Scholar]
  16. Wada M, Nagano N, Furuya Y, et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57 : 50–8. [Google Scholar]
  17. Chin J, Miller SC, Wada M, et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000; 11 : 903–11. [Google Scholar]
  18. Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 1999; 10 : 97–103. [Google Scholar]
  19. Ishii H, Wada M, Furuya Y, et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26 : 175–82. [Google Scholar]
  20. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 1998; 53 : 223–7. [Google Scholar]
  21. Akizawa T, Suzuki M, Tominaga Y, et al. Acute effect of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT). J Am Soc Nephrol 1998; 9 : 561A. [Google Scholar]
  22. Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58 : 436–45. [Google Scholar]
  23. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13 : 1017–24. [Google Scholar]
  24. Coburn J, Barri Y, Turner S, et al. Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2000; 11 : 573A. [Google Scholar]
  25. Lindberg J, Moe S, Goodman W, et al. The calcimimetic AMG-073 reduces parathyroid hormone (PTH), phosphorus and calcium x phosphorus product in secondary hyperparathyroidism. J Am Soc Nephrol 2003; 63 : 248–54. [Google Scholar]
  26. Drueke T, Cunningham J, Goodman W, et al. Short-term treatment of secondary hyperparathyroidism (SHTP) with the calcimimetic agent AMG 073. J Am Soc Nephrol 2001; 12 : 764A. [Google Scholar]
  27. Quarles L, Spiegel D, Curzi M, et al. The effects of one-year treatment with the calcimimetic AMG-073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 2002; 13 : 572A. [Google Scholar]
  28. Chertow G, Danese M, McCary L, Turner S. Self-reported cognitive functioning in hemodialysis patients with secondary HPT : the effect of the calcimimetic AMG-073. J Am Soc Nephrol 2002; 13 : 633A. [Google Scholar]
  29. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350 : 1516–25. [Google Scholar]
  30. Gowen M, Stroup G, Dodds R, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000; 105 : 1595–604. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.